Lung Cancer

  • A study in the New England Journal of Medicine shows more than half of patients with a specific kind of lung cancer are responding positively to a treatment that targets the gene that drives their cancer.
  • A team of researchers from Boston University's Center for Regenerative Medicine and the Pulmonary Center have generated 100 new lines of human induced pluripotent stem cells (iPSC) from individuals with lung diseases, including cystic fibrosis and emphysema.
  • The anti-cancer drug Crizotinib was proposed as an effective drug for treating non-small cell lung cancer, a study published in New England Journal of Medicine said.
  • A collaboration between physicians and scientists at UNC Lineberger Comprehensive Cancer Center and the University of Texas M.D. Anderson Cancer Center has demonstrated that a biomarker called TCF21 may be used to develop a potential screening test for early-stage lung cancer.
  • The way melanoma cells use the immune system to spread and develop into lung tumors may lead to a therapy to decrease development of these tumors, according to Penn State researchers.
  • A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.
  • Early detection is critical for improving cancer survival rates. Yet, one of the deadliest cancers in the United States, lung cancer, is notoriously difficult to detect in its early stages.
  • The most toxic free radical appears responsible for much of the lung damage that can result from oxygen therapy in the critically ill or injured, Medical College of Georgia researchers report.
  • Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
  • For the first time to date, research published in the October edition of the Journal of Thoracic Oncology (JTO) sought to determine the use of chemotherapy in a contemporary, diverse non-small cell lung cancer (NSCLC) population encompassing all patient ages.
  • A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.
  • African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.
More